Clinical trials: Congestive Heart Failure Treated
Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent, Healthy Volunteers
A Study to Compare How Much of the Study Treatment Finerenone Gets Into the Blood When the Same Amount is Taken in One and in Two Tablets of Different Strengths in Healthy Male Participants
In this bioequivalence study, healthy male participants took the study treatment finerenone in the form of one and two tablets of different strengths by mouth.
- Trial name
- NCT07116512
- Testing
- Finerenone (BAY94-8862): intervention A, Finerenone (BAY94-8862): intervention B
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bayer
Congestive Heart Failure
Echocardiography and Peak Endocardial Acceleration (PEA) Measurements in Cardiac Resynchronization Therapy (CRT)
This study used an external endocardial acceleration sensor (sonR sensor), placed on the patient's chest, to time the closure of aortic and mitral valves, and compared its performance with echocardiography.
- Trial name
- NCT01066078
- Testing
- Echocardiography and SonR recording
- Where
- 4 sites in France
- Volunteers
- 216 people
- Sponsor
- LivaNova
Congestive Heart Failure
A Clinical Study Assessing the Potential of Piboserod for the Treatment of Heart Failure
The purpose of this study is to determine whether piboserod, a serotonin-4 receptor antagonist, is effective for the treatment of patients with congestive heart failure.
- Trial name
- NCT00421746
- Testing
- Piboserod
- Where
- 17 sites in Denmark, Norway and 1 more
- Volunteers
- 137 people
- Sponsor
- Bio-Medisinsk Innovasjon
Ischemic Heart Failure, CABG-patients
hiPSC-CMs-loaded Chitosan Patch to Treat Severe Chronic Ischemic Heart Disease
This is an exploratory study. A total of 16 patients meeting the inclusion and exclusion criteria and awaiting coronary artery bypass grafting (CABG) surgery will be enrolled.
- Trial name
- NCT07471698
- Testing
- HiCM-188 Chitosan Patch, Blank Chitosan Patch
- Where
- China
- Volunteers
- 16 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Dilated Cardiomyopathy
Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy
This study is designed to assess the safety profile and the efficacy of cardiac repair cells (CRCs) administered via catheter in treating patients with dilated cardiomyopathy (DCM).
- Trial name
- NCT01020968
- Testing
- Ixmyelocel-T, Vehicle Control
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Vericel Corporation
Acute Heart Failure, Acute Decompensation of Chronic Heart Failure
Tezosentan in the Treatment of Acute Heart Failure
The randomized patients with acute heart failure will be stratified based on the presence or absence of a Swan-Ganz catheter and assigned to receive either tezosentan 5 mg/h for the first 30 minutes and 1 mg/h thereafter or…
- Conditions
- Acute Heart Failure, Acute Decompensation of Chronic Heart Failure, New Onset of Heart Failure
- Trial name
- VERITAS 2 (NCT00524433)
- Testing
- tezosentan
- Where
- 42 sites in United States, Australia and 6 more
- Volunteers
- 713 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Acute Decompensated Heart Failure
IC14 for Treatment of Acute Decompensated Heart Failure
The goal of this clinical trial is to learn if drug atibuclimab (IC14) works to treat adults hospitalized with acute decompensated heart failure (ADHF). It will also learn about the safety of IC14.
- Trial name
- NCT06556810
- Testing
- Atibuclimab (IC14)
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Implicit Bioscience
Tricuspid Regurgitation, Tricuspid Valve Insufficiency
Retrospective Prospective Multicentric Clinical Follow up of Patients After Being Treated With TricValve®
Retrospective prospective Multicentric clinical follow up of patients with severe tricuspid regurgitation after being treated with the TricValve® Transcatheter Bicaval Valves System.
- Conditions
- Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Insufficiency, Heart Failure
- Trial name
- NCT05114850
- Where
- 28 sites in Austria, Belgium and 3 more
- Volunteers
- 450 people
- Sponsor
- P+F Products + Features GmbH
Ischemic Heart Disease
Autologous Cell Therapy for Ischemic Heart Failure
The aim of this clinical study is to investigate the safety and feasibility of Autologous Muscle-derived Cells (AMDC; a preparation of a patient's own cells) as a treatment for patients with advanced heart failure caused by…
- Trial name
- NCT01353690
- Testing
- AMDC
- Where
- 2 sites in Canada
- Volunteers
- 9 people
- Sponsor
- Cook MyoSite
Heart Failure, Volume Overload
Safety & Feasibility of DSR TherApy in Heart FAiluRe pAtients With Persistent Congestion
Feasibility and safety study of the alfapump DSR system in the treatment of volume overloaded heart failure subjects receiving high doses of loop diuretics.
- Trial name
- SAHARA (NCT04882358)
- Testing
- ALFAPUMP DSR (DIRECT SODIUM REMOVAL) SYSTEM, SGLT2 inhibitor
- Where
- 2 sites in Georgia
- Volunteers
- 24 people
- Sponsor
- Sequana Medical N.V.
Chronic Heart Failure With Reduced Ejection Fraction
An Observational Study to Learn More About Vericiguat Treatment Patterns and Its Safety in People With Chronic Heart Failure With Reduced Ejection Fraction in Routine Medical Care in the United States
This is an observational study in which data already collected from people with chronic heart failure with reduced ejection fraction (HFrEF) are studied.
- Trial name
- HOVER (NCT06363110)
- Testing
- Vericiguat (Verquvo, BAY1021189)
- Where
- United States
- Volunteers
- 1,400 people
- Sponsor
- Bayer
Coronary Artery Bypass Grafting (CABG), Chronic Heart Failure
A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure
B2278 is a human umbilical cord mesenchymal stem cell (HucMSCs) injection derived from the umbilical cord. It has the advantages of stronger immune regulation, stronger expansion capacity, lower immunogenicity, and greater…
- Conditions
- Coronary Artery Bypass Grafting (CABG), Chronic Heart Failure, Chronic Ischemic Cardiomyopathy
- Trial name
- NCT07265349
- Testing
- Mesenchymal stem cells(HucMSCs), CABG
- Where
- 4 sites in China
- Volunteers
- 51 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Heart Failure Class II or III
C-Cure Clinical Trial
The purpose of this clinical trial is to evaluate the feasibility, safety and efficacy of left ventricular endocardial injection of guided bone marrow-derived cardiopoietic cells (C-Cure) in the setting of chronic heart failure…
- Trial name
- NCT00810238
- Testing
- C-Cure
- Where
- 8 sites in Belgium, Serbia
- Volunteers
- 240 people
- Sponsor
- Celyad Oncology SA
Severe Sepsis, Acute Heart Failure
Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial
The purpose of this study is to evaluate the impact that the Venus 1000 non-invasive CVP system has on the management of emergency department (ED) patients with fluid sensitive conditions.
- Trial name
- NCT02258984
- Testing
- Mespere Venus 1000 Non-Invasive CVP System
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Mespere Lifesciences Inc.
Heart Failure, Congestive Heart Failure
Alfapump Direct Sodium Removal (DSR) Feasibility Study
First in Human feasibility and sfafety study of the alfapump DSR system in the treatment of Heart failure subects resistant to diuretic therapy.
- Conditions
- Heart Failure, Congestive Heart Failure, Cardiorenal Syndrome, Volume Overload
- Trial name
- RED DESERT (NCT04116034)
- Testing
- alfapump DSR system
- Where
- 2 sites in Belgium, Georgia
- Volunteers
- 8 people
- Sponsor
- Sequana Medical N.V.
Heart Failure, Congestive, Heart Decompensation
Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure
The study will evaluate the safety and efficacy of intravenous infusion of carperitide using pressure measurements inside the heart and great vessels and measuring carperitide concentration in the blood.
- Conditions
- Heart Failure, Congestive, Heart Decompensation, Left Ventricular Failure, Myocardiopathies
- Trial name
- NCT00259038
- Testing
- Carperitide
- Where
- 34 sites in United States, Canada
- Volunteers
- 162 people
- Sponsor
- Daiichi Sankyo
Heart Failure, Reduced Ejection Fraction
Observation of Italian Patients With Heart Failure Being Treated With Dapagliflozin in Clinical Practice
This is an observational, non-interventional, longitudinal prospective descriptive study including participants diagnosed with Heart Failure with reduced Ejection Fraction (HFrEF) in Italy and initiated on treatment with…
- Trial name
- EVOLUTION-HF (NCT05250011)
- Testing
- Dapagliflozin
- Where
- 11 sites in Italy
- Volunteers
- 252 people
- Sponsor
- AstraZeneca
Heart Failure
Clinical Evaluation of HW005 Ventricular Assist System for the Treatment of Advanced Heart Failure in Japan
The purpose of the study is to evaluate the safety and effectiveness of the HW005 System in patients listed for cardiac transplantation with refractory, advanced heart failure at risk of death.
- Trial name
- HW005 (NCT02091440)
- Testing
- Implant of the HW005 Ventricular Assist System.
- Where
- 5 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure, Acute Myocardial Infarction
Carvedilol Vascular Efficacy Trial
Beta-blockers should be administered to all patients with heart failure stages II to IV NYHA. It should also be administered to patients with stage I after myocardial infarction.
- Trial name
- CARVEDIA (NCT01484327)
- Testing
- Carvedilol
- Where
- Greece
- Volunteers
- 415 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Heart Failure
Study to Assess the Bioavailability of Different Formulations of AZD9977 and Dapagliflozin and Influence of Food in Selected Formulations in Healthy Volunteers
The primary purpose of the study is to evaluate relative bioavailability of AZD9977 and dapagliflozin and compare the plasma concentration time profiles after dosing with different capsule formulations containing both AZD9977 and…
- Trial name
- NCT04798222
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AstraZeneca